Erin Floyd
Medical · Mullins, SCNPI 1508127911
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 302 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations.
Across 302 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$666
- AbbVie$594
- Lilly USA, LLC$490
- Novo Nordisk$430
- Pfizer$406
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$222
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,56099%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 44 | $666 |
| AbbVie | 65 | $594 |
| Lilly USA, LLC | 31 | $490 |
| Novo Nordisk | 23 | $430 |
| Pfizer | 27 | $406 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $222 |
| GSK | 12 | $208 |
| Bayer | 14 | $186 |
| Novartis | 10 | $172 |
| Dexcom, Inc. | 5 | $145 |
| Exact Sciences | 7 | $137 |
| Boehringer Ingelheim | 6 | $122 |
| Amgen | 5 | $88 |
| Mylan Specialty L.p. | 4 | $77 |
| Sanofi-aventis U.S. LLC | 3 | $69 |
| Amarin Pharma, Inc. | 4 | $63 |
| Axsome Therapeutics, Inc. | 3 | $53 |
| Astellas Pharma US Inc | 3 | $47 |
| Abbott | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Merck | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Nestle Healthcare Nutrition Inc. | 1 | $26 |
| Corium, LLC | 1 | $24 |
| Corcept Therapeutics | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Sanofi | 1 | $19 |
| Ardelyx, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$4,592 in reported general payments places this provider in the 85th percentile of 384 medical providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 226 | $240,539 |
| OzempicSemaglutide | 77 | $117,317 |
| TrulicityDulaglutide | 71 | $105,173 |
| MounjaroTirzepatide | 89 | $97,655 |
| FarxigaDapagliflozin Propanediol | 53 | $70,908 |
| EliquisApixaban | 66 | $57,297 |
| XareltoRivaroxaban | 48 | $44,574 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $42,991 |
| MyrbetriqMirabegron | 36 | $31,333 |
| JanuviaSitagliptin Phosphate | 41 | $29,129 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $20,101 |
| LinzessLinaclotide | 28 | $16,988 |
| EntrestoSacubitril/Valsartan | 13 | $15,559 |
| Repatha SureclickEvolocumab | 11 | $12,343 |
| TrulancePlecanatide | 15 | $10,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $122 | $240,539226 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $490 | $202,828160 claims |
| Novo NordiskOzempic | $430 | $117,31777 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere, Symbicort | $666 | $87,00985 claims |
| PfizerEliquis | $406 | $57,29766 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $208 | $51,88275 claims |
| Astellas Pharma US IncMyrbetriq | $47 | $31,33336 claims |
| MerckJanuvia | $32 | $29,12941 claims |
| AbbVieLinzess | $594 | $16,98828 claims |
| NovartisEntresto | $172 | $15,55913 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $222 | $10,08415 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $15 | $7,39315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 384 medical providers in South Carolina.
Other medical in Mullins
- Christopher ThompsonSpartanburg$78K
- Laura BuchGreenville$73K
- Suzanne SmithWest Columbia$39K
- Stavros ChrysostomidesColumbia$39K
- Ethan CaseySpartanburg$24K
- Jessica HallColumbia$22K
- Mary MacdonaldCharleston$20K
- Cameron PappasGreenville$18K
- Leslie RumbautGrenville$18K
- Claire DukeGreenville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.